清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia

Blinatumoab公司 医学 卡奇霉素 嵌合抗原受体 内科学 白细胞清除术 推车 肿瘤科 免疫学 白血病 胃肠病学 免疫疗法 抗体 癌症 淋巴细胞白血病 干细胞 川地34 生物 遗传学 机械工程 工程类
作者
Valeria Ceolin,Erica Brivio,Susan R. Rheingold,Allison Barz Leahy,Britta Vormoor,Maureen M. O’Brien,Jeremy D. Rubinstein,Krzysztof Kałwak,Barbara De Moerloose,Elad Jacoby,Peter Bader,José Luís Fuster,Franco Locatelli,Peter M. Hoogerbrugge,Friso Calkoen,C. Michel Zwaan
出处
期刊:Blood [Elsevier BV]
卷期号:138 (Supplement 1): 3824-3824 被引量:3
标识
DOI:10.1182/blood-2021-146556
摘要

Abstract Background: Chimeric Antigen Receptor T-cells targeting CD19 (CART-19) have shown promising efficacy for relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The ELIANA trial leading to market authorization of tisagenlecleucel excluded prior therapy with monoclonal antibodies. Blinatumomab prior to CART-19 seems associated with a higher risk of early failure (Pillai, Blood Advances 2019). Inotuzumab ozogamicin (InO) is an anti-CD22 antibody conjugated to calicheamicin. InO as bridging therapy to CART-19 (n=11) was associated with a shorter overall survival (OS) (Dourthe, Leukemia 2021). InO given prior to leukapheresis might impact on the quality of T-cells collected and, when used as bridging, could result in insufficient CD19 positive (CD19+) antigen load and affect CAR T-cell expansion. We report on a cohort of children and young adults with R/R BCP-ALL treated with InO prior to CART-19 infusion. Methods: Data of patients (pts) treated with CART-19 after InO given at any time before and/or after apheresis, irrespective of other anti-leukemic treatments, were collected using a standardized Case Report Form. The study was approved by the ethics committee of the UMC Utrecht (MvdL/is/21/500393) Results: Thirty-nine pts were treated in 10 centers and received CART-19 between July 2016 and April 2021. Thirty-four received commercial tisagenlecleucel and 5 academic products. Median age was 13 years (range 1-23); 25 were male. Four pts (10.3%) had received a prior CART-19 infusion and 15 (38%) blinatumomab, 18 (46%) had been previously transplanted. All pts received at least two doses of InO (range 2-12); 12 before apheresis only (median time 48 days (range 13-560) between last InO dose and apheresis); 27 as bridging therapy (median time 52 days (range 16-257) from last InO dose to CART-19 infusion), including 5 who had also received InO before apheresis. At time of the infusion, 22 pts were in complete remission (CR) (<5% marrow blasts) including 10 with negative minimal residual disease (MRD; <0.01% by flow or <10 -4 by PCR). In all pts receiving InO prior to apheresis viable CART products were manufactured. One product was out-of-specification due to insufficient interferon-γ, but a subsequent production fulfilled release criteria. At day 28 (d28) post infusion 35/39 were in CR (89.7%), of whom 31 (88.6%) were also MRD negative. Four pts (10.3%) did not achieve CR: 3/4 were not in CR at the time of the infusion; all of them received InO as bridging within 2 months before the infusion. With a median follow-up of 12.5 months (range 1-50) after CART-19 infusion, 12-month event free survival (EFS) was 59% (95% confidence interval (CI) [42.0-76.0]) and OS was 79.5% (95% CI [64.6-94.4]). There was no significant difference in OS/EFS between pts who received blinatumomab and InO prior to CART-19 infusion (n=15) and those who received InO only (n=24) (p=0.61 and p=0.37, respectively). Sixteen pts (45.7%) relapsed at median 163 days (range 28-655) after CART-19 infusion; 7/16 (43.8%) had a CD19+ relapse (median 287 days; range 28-655), 8/16 (50.0%) had a CD19 negative (CD19-) relapse (median 163 days; range 136-273) (1 status unknown). There was no significant difference in 12-month OS/EFS between pts who received InO before apheresis or as bridging (OS 83.3% vs 77.8%, p=0.50; EFS 58.3% vs 59.3%, p=0.62); and no difference in d28 MRD response (p=0.57) or incidence of CD19+ or CD19- relapses (p=0.48) between the 2 groups. Twelve of the 35 pts in CR at d28 (34.2%) lost BCA, median 92 days after CART-19 infusion (range 29−294) (1 data not available); 7/12 relapsed, 5/7 with CD19+ relapse. Among the 35 responders, 5/12 pts who received InO before harvesting lost BCA (1 data not available) vs 7/23 pts who received InO as bridging. There was no significant difference in 12-month EFS between pts who received CART-19 with low CD19 burden at start of lymphodepletion chemotherapy (MRD <10 -4 and BCA, n=6) compared to the rest of the population (p=0.30). Conclusion: InO as a bridging strategy to CAR T-19 does not seem to result in inferior response when EFS/OS are compared to published data (Maude, NEJM 2018; Pasquini, Blood Adv, 2020). The ITCC/IntReALL-059 study will treat very high risk first relapsed BCP-ALL pts (very early relapse or presence of TP53 mutation and/or deletion, hypodiploidy, t(1;19)/t(17;19), KTM2A/AF4) with InO reinduction followed by CART, given the poor prognosis with current strategies. Disclosures O'Brien: Jazz: Honoraria; Pfizer: Honoraria, Research Funding. Jacoby: NOVARTIS: Honoraria, Membership on an entity's Board of Directors or advisory committees. Locatelli: Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Miltenyi: Speakers Bureau; Medac: Speakers Bureau; Jazz Pharamceutical: Speakers Bureau; Takeda: Speakers Bureau. Zwaan: SANOFI: Consultancy; NOVARTIS: Consultancy; ROCHE: Consultancy; INCYTE: Consultancy; PFIZER: Consultancy, Research Funding; JAZZ: Other: travel funding, Research Funding; BMS: Research Funding; Abbvie: Research Funding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助cc采纳,获得10
3秒前
王洋洋完成签到 ,获得积分10
8秒前
zzf关闭了zzf文献求助
15秒前
JamesPei应助ceeray23采纳,获得30
15秒前
cc完成签到,获得积分10
17秒前
宝贝完成签到 ,获得积分10
46秒前
科目三应助dingding采纳,获得10
48秒前
1分钟前
研友_Y59785应助常有李采纳,获得10
1分钟前
zhdjj完成签到 ,获得积分10
1分钟前
CC发布了新的文献求助10
1分钟前
Davidjin完成签到,获得积分10
1分钟前
平常的三问完成签到 ,获得积分10
1分钟前
natsu401完成签到 ,获得积分10
1分钟前
我睡觉的时候不困完成签到 ,获得积分10
1分钟前
perfect完成签到 ,获得积分10
2分钟前
星辰大海应助常有李采纳,获得20
2分钟前
2分钟前
神勇的天问完成签到 ,获得积分10
2分钟前
阿狸完成签到 ,获得积分10
2分钟前
ceeray23发布了新的文献求助30
2分钟前
喜悦的鬼神完成签到 ,获得积分10
2分钟前
水晶李完成签到 ,获得积分10
2分钟前
清脆钧关注了科研通微信公众号
3分钟前
Destiny完成签到,获得积分10
3分钟前
仙女完成签到 ,获得积分10
3分钟前
南风完成签到,获得积分10
3分钟前
常有李完成签到,获得积分10
3分钟前
秋思冬念完成签到 ,获得积分10
3分钟前
南北完成签到 ,获得积分10
3分钟前
ceeray23发布了新的文献求助20
3分钟前
畅快的刚完成签到,获得积分10
3分钟前
文献蚂蚁完成签到,获得积分10
3分钟前
BMG完成签到,获得积分10
3分钟前
朝夕之晖完成签到,获得积分10
3分钟前
CGBIO完成签到,获得积分10
3分钟前
zzf完成签到,获得积分10
4分钟前
冷傲半邪完成签到,获得积分10
4分钟前
4分钟前
曾经不言完成签到 ,获得积分10
4分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990732
求助须知:如何正确求助?哪些是违规求助? 3532220
关于积分的说明 11256570
捐赠科研通 3271081
什么是DOI,文献DOI怎么找? 1805229
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234